Backed by a landmark $1 billion contract from the U.S. government, Johnson & Johnson (J&J)—a pharmaceutical leader with over a century of experience—has begun manufacturing a promising COVID-19 vaccine candidate. Notably, this vaccine has not yet entered human trials, and while politically supported, it awaits formal validation from health authorities.
Most vaccine developers are advancing methodically amid the COVID-19 urgency, with the first approved vaccines optimistically expected in 2021 to support massive global campaigns for millions or billions.
Johnson & Johnson, operating 250 subsidiaries across 60 countries, announced this deal on March 30, 2020, per Reuters. The agreement ensures capacity for at least one billion ready-to-use doses, a critical step forward.
J&J has selected a lead candidate and initiated production, though human trials are slated for September 2020. No health authority approvals exist yet, reflecting the pandemic's demands. Scientific leader Paul Stoffels described it as a "high-risk program requiring a different organization."
The U.S. Department of Health's Biomedical Advanced Research and Development Authority (BARDA) provides crucial support and funding. GAVI CEO Seth Berkley noted that prioritizing top candidates minimizes risks in such scenarios.
BARDA also backs Moderna's mRNA-1273 vaccine, which began Phase I trials in mid-March 2020 with 45 healthy adults aged 18-55.
